[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376977-105":59,"doc-detail-376977-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","complement-system-in-anti-cd20-mab-therapy-for-cancer-a-mini-review","Complement system in Anti-CD20 mAb therapy for cancer - A mini-review","","The complement system is a key component of innate immunity, contributing to pathogen and abnormal cell clearance via complement-dependent cytotoxicity (CDC). Anti-CD20 monoclonal antibodies, such as rituximab and ofatumumab, are established therapies for lymphoid malignancies, with CDC as a major driver of anti-cancer activity. Despite this, clinical limitations remain, including side effects and reduced potency in certain patients. The review synthesizes evidence on complement regulation and potential complement component targeting to improve anti-CD20 mAb efficacy in lymphoma therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/complement-system-in-anti-cd20-mab-therapy-for-cancer-a-mini-review/376977/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/complement-system-in-anti-cd20-mab-therapy-for-cancer-a-mini-review/376977.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is the complement system important in innate immunity and cancer clearance?","Question",{"text":112,"@type":113},"The complement system drives innate immune defense and contributes to clearance of invading pathogens and cancerous host cells through complement-dependent cytotoxicity (CDC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do anti-CD20 monoclonal antibodies work against lymphoma?",{"text":117,"@type":113},"Anti-CD20 mAbs such as rituximab and ofatumumab are established treatments for lymphoid malignancies, and CDC is one of the main mechanisms supporting their anti-cancer activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical challenges limit anti-CD20 antibody therapy?",{"text":121,"@type":113},"Anti-CD20 can cause clinical side effects, and some patients show low potency or insufficient effectiveness even when the dosage is increased.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},376977,1790767009,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Research Article  \nComplement system in Anti-CD20 mAb therapy for cancer: A mini-review  \nYiwen Gao􀀁  \nInternational Journal of Immunopathology and Pharmacology Volume 37: 1–12  \n© The Author(s) 2023  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/03946320231181464](DOI: 10.1177/03946320231181464)  \n[journals.sagepub.com/home/iji](journals.sagepub.com/home/iji)  \nAbstract  \nThe complement system is an important part of innate immunity. Through complement-dependent cytotoxicity (CDC), it plays an important role in the clearance of invading pathogens but also cancerous host cells. Therapy with anti-CD20 monoclonal antibodies (mAbs), for example, rituximab and ofatumumab, is a well-established treatment for lymphoid malignancies, and CDC is one of the main mechanisms underlying their anti-cancer activity. However, there are still some issues with the clinical application of anti-CD20 antibodies. On the one hand, anti-CD20 can cause some clinical side effects; on the other hand, anti-CD20 has low potency in some patients, and increasing the dosage does not enhance its effectiveness in these patients. Previous studies have reported that a gain-of-function in a certain complement component can boost the cytolytic activity of anti-CD20 mAbs. Through reviewing the literature on complement system control and antiCD20 mAbs, this article aims to provide a thorough understanding of the potential of targeting complement components in lymphoma therapy.  \nKeywords  \nInnate immunity, complement system, anti-CD20, anti-cancer, monoclonal antibody therapy  \nDate received: 6 February 2023; accepted: 4 May 2023  \nIntroduction  \nLymphoma is a group of cancers that start in the lymph system. Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are two main types of lymphoma, yet there also exist additional 1,2 subclasses of lymphoma based on lymphoid lineage cells that expand and undergo malignant transformation.3,4 Lymphoma can occur in all age groups, yet HL is more common among people aged 15– 39 years and 75 years or older than other age groups while the rates of NHL grow higher as people get old.4 In 2020, HL and NHL accounted for 23,376 and 259,793 deaths globally, respectively.5,6 Though HL is relatively rare, it is the most common type of cancer among teens aged 15– 19 years.6  \nThanks to the development of antibody therapy, the survival rate of lymphoma has increased. Monoclonal antibodies (mAbs) have been developed into a mature  \nstrategy for cancer treatment for the past 20 years; however, there is still much space for improvement, in particular antiCD20 mAbs, which have been reported to have various detrimental symptoms and/or low response in some patients.7–10 Manipulating complement cascade can serve as an effective strategy to increase the anti-cancer efficacy of anti-CD20 mAbs.1,2, 11–14  \nIn innate immunity, the complement system is a key component. The activation of the complement cascade is strictly restricted by different regulators in order to protect  \nXinjiang Production and Construction Corps Hospital, 5 Division Hospital 84 Regiment Branch, Shuanghe, China  \nCorresponding author:  \nYiwen Gao, Xinjiang Production and Construction Corps, 5 Division Hospital 84 Regiment Branch Liguo Road, Shuanghe 833408, China.  \nEmail: [gao_yiwen@sina.cn](gao_yiwen@sina.cn)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nhost tissues from being attacked, though, it ","cbCaiojiVSenrbmT","https://ap.wps.com/l/cbCaiojiVSenrbmT","pdf",1459748,12,"English","# Abstract\n# Introduction\n## Complement system control and anti-CD20 mAbs\n## The activation and regulation of complement system\n### Complement cascade pathways","[{\"question\":\"Why is the complement system important in innate immunity and cancer clearance?\",\"answer\":\"The complement system drives innate immune defense and contributes to clearance of invading pathogens and cancerous host cells through complement-dependent cytotoxicity (CDC).\"},{\"question\":\"How do anti-CD20 monoclonal antibodies work against lymphoma?\",\"answer\":\"Anti-CD20 mAbs such as rituximab and ofatumumab are established treatments for lymphoid malignancies, and CDC is one of the main mechanisms supporting their anti-cancer activity.\"},{\"question\":\"What clinical challenges limit anti-CD20 antibody therapy?\",\"answer\":\"Anti-CD20 can cause clinical side effects, and some patients show low potency or insufficient effectiveness even when the dosage is increased.\"}]","Complement system in Anti-CD20 mAb therapy for cancer - A mini-review | PDF",1790222455]